Success Metrics

Clinical Success Rate
57.1%

Based on 4 completed trials

Completion Rate
57%(4/7)
Active Trials
2(13%)
Results Posted
50%(2 trials)
Terminated
3(20%)

Phase Distribution

Ph not_applicable
7
47%
Ph phase_1
2
13%
Ph phase_3
1
7%
Ph phase_2
4
27%

Phase Distribution

2

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
2(14.3%)
Phase 2Efficacy & side effects
4(28.6%)
Phase 3Large-scale testing
1(7.1%)
N/ANon-phased studies
7(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

40.0%

4 of 10 finished

Non-Completion Rate

60.0%

6 ended early

Currently Active

2

trials recruiting

Total Trials

15

all time

Status Distribution
Active(2)
Completed(4)
Terminated(6)
Other(3)

Detailed Status

Completed4
Withdrawn3
Terminated3
unknown3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
15
Active
2
Success Rate
57.1%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (14.3%)
Phase 24 (28.6%)
Phase 31 (7.1%)
N/A7 (50.0%)

Trials by Status

withdrawn320%
completed427%
recruiting213%
terminated320%
unknown320%

Recent Activity

2 active trials
Showing 5 of 15
completedphase_2

Stereotaxic Irradiation of Hepatocellular Carcinoma

NCT01165346
withdrawnnot_applicable

Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis

NCT01847495
completednot_applicable

CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer

NCT01985828
recruitingnot_applicable

A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

NCT01890590
withdrawnnot_applicable

Stereotactic Radiosurgery for Soft Tissue Sarcoma

NCT02706171
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT01165346Phase 2

Stereotaxic Irradiation of Hepatocellular Carcinoma

Completed
NCT01847495Not Applicable

Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis

Withdrawn
NCT01985828Not Applicable

CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer

Completed
NCT01890590Not Applicable

A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

Recruiting
NCT02706171Not Applicable

Stereotactic Radiosurgery for Soft Tissue Sarcoma

Withdrawn
NCT04998552Not Applicable

Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma

Recruiting
NCT03284151

Focused Stereotactic Radiation Treatment of Prostatic Adenocarcinoma

Unknown
NCT02716207Not Applicable

Phase ǀ Study on Pancreatic Cancer Treated by CyberKnife

Completed
NCT02707328Phase 1

Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

Terminated
NCT01188486Not Applicable

Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

Terminated
NCT00456612Phase 1

Radiosurgery for Glioblastoma Multiforme

Terminated
NCT00386919Phase 2

Short Course of Radiation for Gliomas in Elderly Patients

Completed
NCT02363218Phase 2

Study on Effectiveness and Safety of Hepatocellular Carcinoma Patients Treated With CyberKnife

Unknown
NCT02406105Phase 2

An Effectiveness and Toxicity of CyberKnife Based Radiosurgery for Parkinson Disease

Unknown
NCT01327521Phase 3

Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma

Withdrawn

All 15 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
15